No Data
No Data
Jiancheng Holdings [01630] now reports HK$0.033, a decrease of 13.16%
As of 13:27, Jiancheng Holdings [01630] reported HK$0.033, down HK$0.005 or 13.16% from yesterday's closing price, with a turnover of HK$0.04 million. Today's high price was HK$0.033 and the lowest price was HK$0.033. Based on yesterday's closing price, the 10-day average price was HK$0.04, and the 50-day average price was HK$0.04. The current price-earnings ratio was 4.81 times, and the 14-day strong and weak index was reported at 42.86.
Jiancheng Holdings [01630] now reports HK$0.031, a decrease of 11.43%
As of 14:29, Jiancheng Holdings [01630] reported HK$0.031, down HK$0.004 or 11.43% from yesterday's closing price, with a turnover of HK$0.47 million. Today's high price was HK$0.031 and the lowest price was HK$0.031. Based on yesterday's closing price, the 10-day average price was HK$0.04, and the 50-day average price was HK$0.04. The current price-earnings ratio was 4.43 times, and the 14-day strength and weakness index was reported at 30.00.
KIN SHING HLDGS: 2023/24 Interim Report
Aiwei Electronics (688798.SH): At present, it has built a reliability laboratory and testing center of about 6,000 square meters
Gelonghui, December 4, when receiving a survey from institutional investors recently, said that the company has now built a reliability laboratory and testing center of about 6,000 square meters, and we will continue to strengthen the construction of laboratories and testing centers in the future. 688798.SH Our own reliability laboratory can provide higher and more stringent reliability guarantees compared to outsourced third party testing, thus protecting the reliability and high quality of Aiwei products in various fields such as mobile phones, AIOT, industry, and automobiles. High standards of reliability verification have become the standard workflow for the quality assurance of Aiwei products. Test center includes CP
Kanghui Pharmaceutical (603139.SH): All new pharmaceutical production bases have been built
Gelonghui November 30: Some investors asked Kanghui Pharmaceutical (603139.SH) on the investor interactive platform, “Has the company submitted an application for the GMP inspection company to build a new pharmaceutical production base?” The company said that all of the company's new pharmaceutical production bases have been built, and preparations for GMP compliance checks are currently being carried out. If relevant progress is made in the future, the company will promptly issue relevant announcements.
KIN SHING HLDGS: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023
No Data